

Discovery research for a first-in-class lead live-microbial gene therapy to control gut-GVHD



IMMUNOLOGY	Lead
Product Type	Microbial Gene Therapy (Engineered LBP)
Indication	GVHD (Graft-versus-Hose Disease)
Target	Regulatory T cells
MoA(Mechanism of Action)	Regulation of gut-GVHD pathology through epithelial protection and immune system control by a gut-GVHD-targeted payload-expressing microbial gene therapy.
Competitiveness	<ul style="list-style-type: none">• DualSET™ Platform: Screening of functional microbiota and precise gene editing applied directly to the selected functional microbiota.• Targeted Mechanism: This therapy delivers disease-targeting molecules that directly regulate T cell activity, maintain gut microbiota and immune system balance, protect intestinal epithelial cells, and suppress disease progression.• Minimal Side Effects: Unlike conventional targeted therapies and small-molecule inhibitors that cause severe side effects like myelosuppression and infections, this therapy induces immune homeostasis and regulates the gut microbiota with minimal or no side effects.
Development Stage	Lead
Route of Administration	Oral